{
  "source": "PA-Notification-Vowst.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1416-2\nProgram Prior Authorization/Notification\nMedication Vowst™ (fecal microbiota spores, live-brpk)\nP&T Approval Date 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nVowst is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in\nindividuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).\n2. Coverage Criteriaa:\nA. Authorization\n1. Vowst will be approved based on all of the following criteria:\na. Diagnosis of recurrent Clostridioides difficile infection (rCDI)\n-AND-\nb. Patient is 18 years of age or older\n-AND-\nc. Patient has completed antibiotic treatment for rCDI 2 to 4 days prior to initiating\nVowst\n-AND-\nd. Vowst is used to prevent the recurrence of CDI\nAuthorization will be issued for 1 month\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place\n• Prior Authorization/Medical Necessity may be in place\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Vowst [package insert]. Cambridge, MA: Seres Therapeutics, Inc.; April 2023.\nProgram Prior Authorization/Notification - Vowst™ (fecal microbiota spores,\nlive-brpk)\nChange Control\n7/2023 New program.\n7/2024 Annual review with no changes.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}